Iovance Biotherapeutics, Inc. IOVA
Price alert —
Sign in to get a one-time email the moment IOVA crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · IOVA
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.1B | $-0.1B | $-0.1B | $-0.1B | -110.7% | -113.5% |
| 2025-12-31 | $0.1B | $-0.1B | $-0.1B | $-0.1B | -82.9% | -84.7% |
| 2025-09-30 | $0.1B | $-0.1B | $-0.1B | $-0.1B | -135.3% | -133.1% |
| 2025-06-30 | $0.1B | $-0.1B | $-0.1B | $-0.1B | -186.2% | -189.8% |
| 2025-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -235.5% | -245.8% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare IOVA vs peers
Line IOVA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with IOVA
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -0.19 | -0.15 | -23.8% | +2.0% |
| 2026-02-24 | -0.18 | -0.18 | -2.0% | +1.3% |
| 2025-11-06 | -0.25 | -0.26 | +2.9% | -0.4% |
| 2025-08-07 | -0.33 | -0.28 | -19.4% | -20.1% |
| 2025-05-08 | -0.36 | -0.24 | -52.3% | -44.8% |
| 2025-02-26 | -0.26 | -0.27 | +2.9% | -1.7% |
| 2024-11-07 | -0.28 | -0.30 | +7.2% | -13.8% |
| 2024-08-08 | -0.34 | -0.35 | +3.7% | +24.9% |
| 2024-05-08 | -0.42 | -0.41 | -2.5% | +0.5% |
| 2024-02-28 | -0.45 | -0.43 | -4.8% | -8.7% |
| 2023-11-07 | -0.46 | -0.46 | -1.0% | -3.5% |
| 2023-08-08 | -0.47 | -0.79 | +40.2% | +6.4% |
| 2023-05-09 | -0.50 | -0.73 | +31.1% | +3.8% |
| 2023-02-28 | -0.64 | -0.64 | -0.6% | +0.1% |
| 2022-11-03 | -0.63 | -0.64 | +1.7% | +4.3% |
| 2022-08-04 | -0.63 | -0.61 | -2.9% | -2.9% |
| 2022-05-05 | -0.58 | -0.63 | +7.7% | -2.5% |
| 2022-02-24 | -0.63 | -0.56 | -13.1% | +4.7% |
| 2021-11-04 | -0.55 | -0.53 | -4.5% | +2.0% |
| 2021-08-05 | -0.53 | -0.51 | -3.6% | -1.6% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| IOVA ★ | $2B | — | -15.6 | 7.8 | -6.1 | 3.0 | 39.4% | 44.8% | — | -6.68% |
| LLY | — | 41.8 | 26.3 | — | 30.1 | — | 82.8% | 55.5% | 169.9% | — |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | — | 36.0 | 13.2 | — | 12.1 | 6.9 | 76.7% | 4.9% | — | — |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | — | 19.1 | 8.8 | — | 7.6 | — | 74.8% | 5.4% | -10.1% | — |
| TMO | — | 29.2 | 19.5 | — | 21.1 | — | 40.9% | 6.2% | 11.3% | — |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 34.66%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 31,080,505 | 6.96% |
| MHR Fund Management, LLC | 28,967,103 | 6.49% |
| State Street Corporation | 17,448,108 | 3.91% |
| Vanguard Capital Management LLC | 16,617,737 | 3.72% |
| Two Sigma Investments, LP | 13,687,433 | 3.07% |
| Vanguard Portfolio Management LLC | 11,700,844 | 2.62% |
| Millennium Management Llc | 9,414,292 | 2.11% |
| Goldman Sachs Group Inc | 8,760,060 | 1.96% |
| Geode Capital Management, LLC | 8,572,598 | 1.92% |
| Invenomic Capital Management, LP | 8,495,551 | 1.90% |
Insider activity · 90d
5 buys / 0 sells · ratio 5.0 · Finnhub
- Dukes Iain D. BUY 180,632
- Countouriotis Athena BUY 90,316
- Puri Raj K. BUY 15,000
- Maynard Ryan D BUY 90,316
- WEISER MICHAEL BUY 90,316
- Vogt Frederick G M 109,382
- Vogt Frederick G F 562,492 @ $4.23
- Vogt Frederick G M 569,130
- GRAF FINCKENSTEIN FRIEDRICH M 54,691
- GRAF FINCKENSTEIN FRIEDRICH F 140,111 @ $4.23
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-02 | FORM 8-K | view · |
| 4 | 2026-06-18 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-18 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-18 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-18 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-18 | OWNERSHIP DOCUMENT | view · |
| 8-K | 2026-06-10 | FORM 8-K | view · |
| 4 | 2026-06-09 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-09 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-09 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-09 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-06-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-05-13 | OWNERSHIP DOCUMENT | view · |
| 8-K | 2026-05-07 | FORM 8-K | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| DEF 14A | 2026-04-28 | DEF 14A | view · |
| 8-K | 2026-03-20 | FORM 8-K | view · |
| 4 | 2026-03-11 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-11 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-11 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-11 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-11 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-11 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-06 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-06 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-06 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-06 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-04 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-04 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-04 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-03-04 | OWNERSHIP DOCUMENT | view · |
| 4 | 2026-02-26 | OWNERSHIP DOCUMENT | view · |
| 10-K | 2026-02-24 | 10-K | view · |
| 8-K | 2026-02-24 | FORM 8-K | view · |
| 4 | 2026-02-12 | OWNERSHIP DOCUMENT | view · |
| 8-K | 2026-01-09 | FORM 8-K | view · |
| 4 | 2025-12-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-12-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-12-03 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-12-03 | OWNERSHIP DOCUMENT | view · |
| 10-Q | 2025-11-06 | 10-Q | view · |
| 8-K | 2025-11-06 | FORM 8-K | view · |
| 4 | 2025-09-04 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-09-04 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-09-04 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-09-04 | OWNERSHIP DOCUMENT | view · |
| 8-K | 2025-08-29 | FORM 8-K | view · |
| 8-K | 2025-08-22 | FORM 8-K | view · |
| 8-K | 2025-08-19 | FORM 8-K | view · |
| 4 | 2025-08-08 | OWNERSHIP DOCUMENT | view · |
| 10-Q | 2025-08-07 | 10-Q | view · |
| 8-K | 2025-08-07 | FORM 8-K | view · |
| 8-K | 2025-07-15 | FORM 8-K | view · |
| 8-K | 2025-07-03 | FORM 8-K | view · |
| 4 | 2025-06-17 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-06-17 | OWNERSHIP DOCUMENT | view · |
| 4 | 2025-06-17 | OWNERSHIP DOCUMENT | view · |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes…
Options picks · IOVA
ITM + OTM ideas from the latest scanLoading…
Congress trades · IOVA
STOCK Act disclosuresLoading…
SEC filings & insiders · IOVA
EDGAR · liveLoading…
Holders · IOVA
Institutions & insider activityLoading…